Zacks: Analysts Set $19.00 Target Price for Sol Gel Technologies Ltd (SLGL)


Shares of Sol Gel Technologies Ltd (NASDAQ:SLGL) have been assigned a consensus broker rating score of 1.50 (Buy) from the four analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and three have assigned a strong buy recommendation to the company.


Brokers have set a 12-month consensus price objective of $19.00 for the company and are forecasting that the company will post ($0.33) EPS for the current quarter, according to Zacks. Zacks has also assigned Sol Gel Technologies an industry rank of 231 out of 265 based on the ratings given to related companies.

Get Sol Gel Technologies alerts:

A number of equities research analysts recently issued reports on SLGL shares. BMO Capital Markets started coverage on shares of Sol Gel Technologies in a research report on Monday, February 26th. They set an “outperform” rating and a $18.00 target price for the company. JMP Securities started coverage on shares of Sol Gel Technologies in a research report on Monday, February 26th. They set a “market outperform” rating and a $20.00 target price for the company. Jefferies Group started coverage on shares of Sol Gel Technologies in a research report on Monday, February 26th. They set a “buy” rating and a $17.00 target price for the company. Finally, ValuEngine upgraded shares of Sol Gel Technologies from a “sell” rating to a “hold” rating in a research report on Wednesday.


NASDAQ:SLGL opened at $9.02 on Wednesday. Sol Gel Technologies has a 52 week low of $8.00 and a 52 week high of $16.48.

About Sol Gel Technologies

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea; and TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris.

Get a free copy of the Zacks research report on Sol Gel Technologies (SLGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *